CABOMETYX, known generically as cabozantinib, is a prescription medication used in the treatment of various forms of cancer. It is specifically designed to target and inhibit multiple tyrosine kinases, which are enzymes known to promote tumor growth and angiogenesis (the formation of new blood vessels that supply tumors). By blocking these pathways, CABOMETYX can slow or stop the growth of cancer cells and reduce the supply of nutrients to tumors. It is commonly prescribed for the treatment of advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (a type of liver cancer), and medullary thyroid cancer after prior therapies have failed. The effectiveness of CABOMETYX, along with its ability to target multiple pathways involved in tumor growth, makes it a valuable option in the management of these cancers. However, it can also come with a range of side effects, and its use must be carefully monitored by a healthcare professional.